Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance

• Published in: Cancer research communications 2023-12, Vol.3 (12), p.2518-2530
• Main Authors: Banerjee, Debarshi, Boboila, Shuobo, Okochi, Shunpei, Angelastro, James M, Kadenhe-Chiweshe, Angela V, Lopez, Gonzalo, Califano, Andrea, Connolly, Eileen P, Greene, Lloyd A, Yamashiro, Darrell J
• Format: Article
• Language: English
• Subjects: Activating Transcription Factors; Anoikis - genetics; Antineoplastic Agents - pharmacology; Cell Death And Senescence; Cyclic AMP Response Element-Binding Protein; Gene Regulation; Humans; Neuroblastoma - drug therapy; Pediatric Cancers; Progression, Invasion & Metastasis; Small Molecule Agents
• ISSN: 2767-9764; 2767-9764
• DOI: 10.1158/2767-9764.CRC-23-0154

MYCN-amplified neuroblastoma often presents as a highly aggressive metastatic disease with a poor prognosis. Activating transcription factor 5 (ATF5) is implicated in neural cell differentiation and cancer cell survival. Here, we show that ATF5 is highly expressed in patients with stage 4 high-risk neuroblastoma, with increased expression correlating with a poorer prognosis. We demonstrated that ATF5 promotes the metastasis of neuroblastoma cell lines in vivo. Functionally, ATF5 depletion significantly reduced xenograft tumor growth and metastasis of neuroblastoma cells to the bone marrow and liver. Mechanistically, ATF5 endows tumor cells with resistance to anoikis, thereby increasing their survival in systemic circulation and facilitating metastasis. We identified the proapoptotic BCL-2 modifying factor (BMF) as a critical player in ATF5-regulated neuroblastoma anoikis. ATF5 suppresses BMF under suspension conditions at the transcriptional level, promoting anoikis resistance, whereas BMF knockdown significantly prevents ATF5 depletion-induced anoikis. Therapeutically, we showed that a cell-penetrating dominant-negative ATF5 peptide, CP-d/n-ATF5, inhibits neuroblastoma metastasis to the bone marrow and liver by inducing anoikis sensitivity in circulating tumor cells. Our study identified ATF5 as a metastasis promoter and CP-d/n-ATF5 as a potential antimetastatic therapeutic agent for neuroblastoma. This study shows that resistance to anoikis in neuroblastoma is mediated by ATF5 and offers a rationale for targeting ATF5 to treat metastatic neuroblastoma.